Company Description
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Sector:
Healthcare
Industry:
Biotechnology
Get access
to the rating of Finrange stocks
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Rating Finrange Fundamental stock rating for Windtree Therapeutics Inc (WINT): Finrange AI expert score is 15.00 out of 100. The analysis is based on valuation multiples, profitability, debt load, cash flow, and company growth rates.
Index: 15 %Fundamental stock rating for Windtree Therapeutics Inc (WINT): Finrange AI expert score is 15.00 out of 100. The analysis is based on valuation multiples, profitability, debt load, cash flow, and company growth rates.
-
Market cap Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.
- 1.87K
-
EV Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
- 12.49M
-
Beta Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
- -
-
Shares Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
- 26.68K
-
YTD Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
- -99.00 %
Upcoming events Windtree Therapeutics Inc
All events
No upcoming events scheduled
Stock chart Windtree Therapeutics Inc
Quote chart for Windtree Therapeutics Inc (WINT) for the last 12 months. Current price: 0.0003 USD. 52-week low: 0.0001 USD. 52-week high: 0.06 USD. 12-month change: -99.50%.
Stock analysis Windtree Therapeutics Inc
| Indicator | Company | Industry |
|---|---|---|
|
P/E (LTM)
Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.
|
0.0000 | -1.89 |
|
P/BV (LTM)
Shows the ratio of the market price of the share to the current book value.
|
0.09 | 1.83 |
|
EV/EBITDA (LTM)
Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.
|
-0.30 | -1.39 |
|
Net Debt/EBITDA (LTM)
A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.
|
-0.30 | 0.32 |
|
ROE (LTM)
Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.
|
344.56 | -44.50 |
Price change Windtree Therapeutics Inc per year
0.0001$
0.06$
Today share price: 0.0003$. Min: 0.0001$. Max: 0.06$.
Min
Max
Summary analysis Windtree Therapeutics Inc
View top stocks by rating
Get access
to the rating of Finrange stocks
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Shareholder structure Windtree Therapeutics Inc
| Holder | Share |
|---|---|
| Blackstone Alternative Multi-Strategy I | 0.00% |
| Urban Wealth Management, LLC | 0.00% |
Revenue and net income Windtree Therapeutics Inc
All parametersRevenue and net income chart for Windtree Therapeutics Inc (WINT) for 2020-2024. Revenue in 2024: 0.0000 USD. Net income in 2024: -5487000.00 USD.
| Year | Revenue | Net Profit |
|---|---|---|
| 2020 | 0.0000 USD | -30280000.00 USD |
| 2021 | 0.0000 USD | -67636000.00 USD |
| 2022 | 0.0000 USD | -39208000.00 USD |
| 2023 | 0.0000 USD | -20291000.00 USD |
| 2024 | 0.0000 USD | -5487000.00 USD |
Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Address:
- Company name:
-
Windtree Therapeutics Inc
- Issuer ticker:
- WINT
- Country:
- USA
- Exchange:
- NASDAQ
- Currency:
- $
- Stock split:
- 1:50
- Sector:
- Healthcare
- Industry:
- Biotechnology
- Site:
https://windtreetx.com